Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns

Abstract

A prospective study over 15 months in 100 elderly patients with signs of cerebro-vascular impairment demonstrated by psychometric testing that Hydergine (an ergot alkaloid preparation: 4.5 mg daily) compensated the signs of dementia, present in the placebo group, and in some patients actually brought about a significant improvement in mental activity. Similar compensatory effect was also demonstrable in cerebral haemodynamics: in the placebo group there was a progressive increase in cerebral circulation time, an expression of decreased cerebral blood flow, while with Hydergine cerebral circulation time was shortened and stabilized. Serial EEGs, obtained in parallel with psychometric and circulation time tests, demonstrated a marked increase in the 8-10 Hz pattern which corresponds to the physiological alpha activity in this age group. Furthermore, there was a diminished variability in performance in the tested frequency bands with Hydergine, the opposite tendency being obtained in the placebo group.

Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry

“…The attenuation of the delta/theta increase was mostly observed over the temporal regions. Nicergoline itself produced obviously a decrease of delta/theta activity and an increase of alpha and beta activity which confirms our previous studies with this drug in elderly people (Saletu et al, 1979a(Saletu et al, , b, 1990Saletu and Grfinberger, 1985a), but also reports of other investigators concerning CNS effects of ergotalkaloids (Matejcek and Devos, 1976;K6berle and Spiegel, 1984;Kugler et al, 1978). The fact, that the hypoxia-induced slowing of the brain waves was mostly seen over the temporal and parietal regions as well as the observation that nicergoline-induced decrease of delta/theta and increase of beta activity were most pronounced over the temporal and frontal regions were in as much of interest as in our recent brain mapping study in SDAT patients we could demonstrate that, as compared with normals, an increase of delta/theta and a decrease of alpha and beta activity occurred mostly over the parietal and temporal regions (Saletu et al, 1988).…”

A Long-Term Study with Co-Dergocrine Mesylate (Hydergine®) in Healthy Pensioners

“…The compound is consequently considered one of the few clini cally proven 'psychogeriatric' drugs [ Reis berg et al, 1981], Little research has been devoted to long term effects of co-dergocrine mesylate in hu mans. Most therapeutic studies have in volved a duration of treatment of 3 months; in a few instances applications have lasted 6 months, and only 1 controlled study had a longer duration of 15 months [Kugler et al, 1978]. These longer investigations essentially confirmed the effects of co-dergocrine mesy late described in the 3-month studies.…”

Hydergine in Senile Mental Impairment

“…Two 3-month studies [Arrigo et al, 1973;Roubicek et al, 1972] and a 6-month study [Arrigo, 1975] with a daily oral dose of 4.5 mg Hyder gine showed concomitant EEG and clinical improvement, confirming the results of a 6-week study [Herzfeldet al, 1972b], The main finding was an acceleration of the dominant frequency. Similar results were obtained by Wilder and Gonyea [1973] and Biel et al [1976] with 3 mg Hydergine daily for 6 weeks, and by Kugler et al [1978] in a 15-month trial with 4.5 mg Hydergine daily.…”